Alliance for Clinical Trials in Oncology: clinical-trial pipeline
Alliance for Clinical Trials in Oncology is the sponsor of 509 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 69 are not yet finished and 1 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials69
Phase 2/3 and 3160
Countries19
New in 90 days1
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 225 |
| Phase 3 | 153 |
| Not applicable | 91 |
| Phase 1 | 15 |
| Phase 1/2 | 15 |
| Phase 2/3 | 7 |
| Not stated | 2 |
| Early phase 1 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 379 |
| Active, not recruiting | 41 |
| Terminated | 35 |
| Recruiting | 26 |
| Withdrawn or not authorised | 15 |
| Unknown | 9 |
| Not yet recruiting | 2 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 500 |
| Nephrology and urology | 59 |
| Gastroenterology and liver | 43 |
| Rare and genetic diseases | 21 |
| Respiratory | 16 |
| Dermatology | 15 |
| Haematology | 11 |
| Psychiatry and mental health | 8 |
| Women's health and obstetrics | 7 |
| Musculoskeletal | 6 |
| Metabolic and endocrine (diabetes, obesity) | 4 |
| Neurology | 4 |
Countries
| Country | Trials |
|---|---|
| United States | 463 |
| Canada | 89 |
| Puerto Rico | 39 |
| Australia | 8 |
| Ireland | 3 |
| Peru | 3 |
| South Africa | 3 |
| Austria | 2 |
| Belgium | 2 |
| Switzerland | 2 |
| Germany | 2 |
| Spain | 2 |
| France | 2 |
| Israel | 2 |
| Netherlands | 2 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diag… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT04711109 | Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | Phase 3 | Active, not recruiting | Austria, Germany, Spain, United States |
| NCT02375204 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Trea… | Phase 3 | Active, not recruiting | Australia, Belgium, Switzerland, Germany +8 |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | Phase 2 | Recruiting | United States |
| NCT03927027 | Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph No… | Phase 3 | Active, not recruiting | United States |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lympho… | Phase 3 | Recruiting | Canada, United States |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy… | Phase 2/3 | Not yet recruiting | |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability | Not applicable | Recruiting | United States |
| NCT05751668 | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With… | Phase 2 | Active, not recruiting | United States |
| NCT04242095 | Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | Not applicable | Recruiting | United States |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Asso… | Phase 2/3 | Active, not recruiting | United States |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Men… | Phase 2 | Recruiting | United States |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Resp… | Phase 3 | Recruiting | Canada, Puerto Rico, United States |
| NCT05303792 | Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Bl… | Phase 2 | Active, not recruiting | Puerto Rico, United States |
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Canc… | Phase 3 | Active, not recruiting | Puerto Rico, United States |
| NCT05976763 | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Pre… | Phase 3 | Recruiting | United States |
| NCT04114981 | Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Pat… | Phase 3 | Active, not recruiting | Canada, United States |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cel… | Phase 3 | Active, not recruiting | United States |
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) Afte… | Phase 2/3 | Active, not recruiting | Puerto Rico, United States |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast C… | Phase 3 | Active, not recruiting | United States |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-… | Phase 3 | Recruiting | United States |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive B… | Phase 3 | Active, not recruiting | Canada, Puerto Rico, United States |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Col… | Phase 2 | Recruiting | Canada, United States |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized P… | Phase 3 | Active, not recruiting | Canada, United States |
| NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | Not applicable | Recruiting | Puerto Rico, United States |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patient… | Phase 3 | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Alliance for Clinical Trials in Oncology clinical trials: 69 open, 160 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/alliance-for-clinical-trials-in-oncology/, data as of 2026-10-25.